22 results on '"Antonuzzo, L."'
Search Results
2. 91P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC).
3. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
4. 498TiP Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial
5. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC).
6. 422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018).
7. 292P Extended molecular profiling (EMP) and access to targeted treatment (TT) in advanced biliary tract cancer (BTC): Results from the Italian cholangiocarcinoma dataset (ANITA).
8. 108P Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A translational analysis of the TRIPLETE trial.
9. 18P Clinical outcomes in pT4N0 colon cancer (CC) patients: Data from a large, multicenter, real-word cohort.
10. 142P The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study.
11. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
12. LBA22 Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study.
13. 643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors.
14. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
15. PO-0928: Safety and efficacy of concomitant RT and CDK4/6 inhibitors in metastatic breast cancer patients.
16. 6114 POSTER Clinical Outcomes of Bevacizumab (BV) + XELOX Combination for the First-line Treatment of Patients (pts) With Advanced Cancer of the Colon or Rectum (ACRC) – Preliminary Results of the OBELIX Study
17. P-66 Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population.
18. 1497P Cancer patients' awareness about clinical research: The ELPIS study preliminary results.
19. 94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations.
20. 696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP).
21. 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study.
22. PD-016 - Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.